Alqassem Hamdallah Abuarqoub
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alqassem Hamdallah Abuarqoub has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Duaa Abuarqoub
Faculty of Pharmacy and Medical Sciences, University of Petra, Amman 11196, Jordan
4 shared publications - Mais Emad
Faculty of Pharmacy and Medical Sciences, University of Petra, Amman 11196, Jordan
3 shared publications - Majd F. Ellauzi
Al Wafi Academy, Amman 11190, Jordan
2 shared publications - Abdalla Awidi
Cell Therapy Center, The University of Jordan, Amman 11942, Jordan
1 shared publication - Abdolelah Jaradat
Faculty of Pharmacy, Applied Pharmaceutical Sciences and Clinical Pharmacy, Isra University, Amman, Jordan
1 shared publication - Akbar Ali
Universiti Sains Malaysia
1 shared publication
Latest Publications
- Open Access
- 4 October 2026
- Published by MDPI AG in Scientia Pharmaceutica
- Vol. 94 (4) , 90
Natural Phenolic Compounds in Pain Management and Regenerative Medicine: From Molecular Mechanisms to Therapeutic Applications
Natural phenolic compounds are plant-derived compounds known for their potent antioxidant and anti-inflammatory properties. In addition, natural phenolic compounds are being investigated for their potential applications in pain management, and tissue engineering and regenerative medicine. This review aims to emphasize the anti-inflammatory and anti-oxidant effects of natural phenolic compounds and to highlight their important roles in pain management and tissue engineering and regenerative medicine. In pain management, natural phenolic compounds demonstrated promising results in suppressing orofacial, pelvic, neuropathic, and musculoskeletal pain compared to conventional pain management drugs or by synergistically acting with those drugs. While in tissue engineering and regenerative medicine, natural phenolic compounds were found to enhance the differentiation potential of stem cells into different lineages by increasing the expression of differentiation markers and were also found to enhance proliferation and migration of different types of dental stem cells. In conclusion, natural phenolic compounds, due to their unique properties, are promising in protocols of pain management as well as in tissue engineering and regenerative medicine.
- 4 October 2026
- Published by MDPI AG in Scientia Pharmaceutica
- Vol. 94 (4) , 90
Open AccessNatural Phenolic Compounds in Pain Management and Regenerative Medicine: From Molecular Mechanisms to Therapeutic Applications
Natural phenolic compounds are plant-derived compounds known for their potent antioxidant and anti-inflammatory properties. In addition, natural phenolic compounds are being investigated for their potential applications in pain management, and tissue engineering and regenerative medicine. This review aims to emphasize the anti-inflammatory and anti-oxidant effects of natural phenolic compounds and to highlight their important roles in pain management and tissue engineering and regenerative medicine. In pain management, natural phenolic compounds demonstrated promising results in suppressing orofacial, pelvic, neuropathic, and musculoskeletal pain compared to conventional pain management drugs or by synergistically acting with those drugs. While in tissue engineering and regenerative medicine, natural phenolic compounds were found to enhance the differentiation potential of stem cells into different lineages by increasing the expression of differentiation markers and were also found to enhance proliferation and migration of different types of dental stem cells. In conclusion, natural phenolic compounds, due to their unique properties, are promising in protocols of pain management as well as in tissue engineering and regenerative medicine.
- Open Access
- 8 September 2026
- Published by MDPI AG in Journal of Functional Biomaterials
- Vol. 17 (9) , 459
Bioprinting the Craniofacial Region: A New Era in Regenerative Medicine and Dentistry
Background: Three-dimensional (3D) printing and bioprinting have emerged as transformative technologies in tissue engineering and regenerative medicine. Conventional 3D printing enables the fabrication of complex, customizable scaffolds that mimic the native extracellular matrix (ECM), providing mechanical support essential for cell adhesion, proliferation, and differentiation. In contrast, 3D bioprinting integrates biomaterials, growth factors, and living cells into bioinks, allowing the precise layer-by-layer construction of tissue-like structures. Objective: This review aims to highlight recent advances and applications of both conventional 3D printing and 3D bioprinting in regenerative medicine, with a specific focus on craniofacial tissue regeneration. Particular emphasis is placed on the distinct roles of scaffold-based and cell-laden approaches. Methods: A comprehensive analysis of the current literature was conducted to examine both conventional 3D printing and bioprinting approaches used in craniofacial tissue engineering. Emphasis was placed on printing techniques, bioink composition and selection, scaffold design, and cell sources, as well as their applications across multiple tissue types. Results: Recent developments demonstrate that conventional 3D printing enables the fabrication of customizable scaffolds, whereas 3D bioprinting enables the generation of highly organized, cell-laden constructs that closely resemble native tissue architecture. These technologies have shown promising outcomes in developing patient-specific disease models and regenerative implants for craniofacial tissues, including bone, dental, tracheal, ocular, muscle, and neural tissues. Conclusions: 3D printing and bioprinting offer powerful platforms for craniofacial regenerative medicine. Ongoing advancements in bioink formulation, printing precision, and biological integration are expected to further enhance their translational and clinical potential.
- 8 September 2026
- Published by MDPI AG in Journal of Functional Biomaterials
- Vol. 17 (9) , 459
Open AccessBioprinting the Craniofacial Region: A New Era in Regenerative Medicine and Dentistry
Background: Three-dimensional (3D) printing and bioprinting have emerged as transformative technologies in tissue engineering and regenerative medicine. Conventional 3D printing enables the fabrication of complex, customizable scaffolds that mimic the native extracellular matrix (ECM), providing mechanical support essential for cell adhesion, proliferation, and differentiation. In contrast, 3D bioprinting integrates biomaterials, growth factors, and living cells into bioinks, allowing the precise layer-by-layer construction of tissue-like structures. Objective: This review aims to highlight recent advances and applications of both conventional 3D printing and 3D bioprinting in regenerative medicine, with a specific focus on craniofacial tissue regeneration. Particular emphasis is placed on the distinct roles of scaffold-based and cell-laden approaches. Methods: A comprehensive analysis of the current literature was conducted to examine both conventional 3D printing and bioprinting approaches used in craniofacial tissue engineering. Emphasis was placed on printing techniques, bioink composition and selection, scaffold design, and cell sources, as well as their applications across multiple tissue types. Results: Recent developments demonstrate that conventional 3D printing enables the fabrication of customizable scaffolds, whereas 3D bioprinting enables the generation of highly organized, cell-laden constructs that closely resemble native tissue architecture. These technologies have shown promising outcomes in developing patient-specific disease models and regenerative implants for craniofacial tissues, including bone, dental, tracheal, ocular, muscle, and neural tissues. Conclusions: 3D printing and bioprinting offer powerful platforms for craniofacial regenerative medicine. Ongoing advancements in bioink formulation, printing precision, and biological integration are expected to further enhance their translational and clinical potential.
- Open Access
Advancing Sports Injury Treatment Through Cell-Free MSC-Based Therapies: A Narrative Review
Background: Sports-related musculoskeletal injuries, including tendon, ligament, muscle, and cartilage damage, often heal slowly and incompletely. Current treatments may not fully restore tissue function, necessitating regenerative therapies. Objective: This study was conducted to review the therapeutic potential of stem cell-derived extracellular vesicles (EVs) and conditioned medium (CM) as cell-free approaches to treating musculoskeletal injuries in sports medicine. Methods: A narrative review of preclinical and early clinical studies investigating the biological mechanisms and regenerative effects of mesenchymal stem/stromal cell (MSC)-derived EVs and CMs published between 2019 and 2026 was performed by searching Scopus, PubMed, Web of Science, and Google scholar. Results: EVs and CMs contain bioactive molecules, including microRNAs, cytokines, and growth factors, that modulate inflammation, promote tissue repair, enhance angiogenesis, and support extracellular matrix remodeling. Preclinical studies demonstrate improved healing of tendons, ligaments, muscles, and cartilage, while early clinical evidence suggests favorable safety and promising therapeutic outcomes. However, the variety of MSC sources, EV separation methods, characterization procedures, and treatment protocols present major challenges in determining the reliability and therapeutic efficacy of these therapies. Notably, the number of clinical studies on EV and CMs is still limited, and most of the available studies are in vitro studies. Conclusions: MSC-derived EVs and CMs represent promising cell-free regenerative therapies for sports-related musculoskeletal injuries. The available evidence, which demonstrates their ability to enhance healing while avoiding the challenges associated with cell-based therapies, highlights their translational potential. However, most of the studies that are now available are preclinical or early-stage clinical studies, and there is still a limited number of clinical trials. Further well-designed clinical studies are needed to establish standardized protocols and confirm long-term safety.
Open AccessAdvancing Sports Injury Treatment Through Cell-Free MSC-Based Therapies: A Narrative Review
Background: Sports-related musculoskeletal injuries, including tendon, ligament, muscle, and cartilage damage, often heal slowly and incompletely. Current treatments may not fully restore tissue function, necessitating regenerative therapies. Objective: This study was conducted to review the therapeutic potential of stem cell-derived extracellular vesicles (EVs) and conditioned medium (CM) as cell-free approaches to treating musculoskeletal injuries in sports medicine. Methods: A narrative review of preclinical and early clinical studies investigating the biological mechanisms and regenerative effects of mesenchymal stem/stromal cell (MSC)-derived EVs and CMs published between 2019 and 2026 was performed by searching Scopus, PubMed, Web of Science, and Google scholar. Results: EVs and CMs contain bioactive molecules, including microRNAs, cytokines, and growth factors, that modulate inflammation, promote tissue repair, enhance angiogenesis, and support extracellular matrix remodeling. Preclinical studies demonstrate improved healing of tendons, ligaments, muscles, and cartilage, while early clinical evidence suggests favorable safety and promising therapeutic outcomes. However, the variety of MSC sources, EV separation methods, characterization procedures, and treatment protocols present major challenges in determining the reliability and therapeutic efficacy of these therapies. Notably, the number of clinical studies on EV and CMs is still limited, and most of the available studies are in vitro studies. Conclusions: MSC-derived EVs and CMs represent promising cell-free regenerative therapies for sports-related musculoskeletal injuries. The available evidence, which demonstrates their ability to enhance healing while avoiding the challenges associated with cell-based therapies, highlights their translational potential. However, most of the studies that are now available are preclinical or early-stage clinical studies, and there is still a limited number of clinical trials. Further well-designed clinical studies are needed to establish standardized protocols and confirm long-term safety.
- 3 April 2026
- Published by Taylor & Francis in Epigenomics
- Vol. 18 (4) , 397-410
Computational-based integrative methylome-transcriptome analysis reveals widespread enhancer hypomethylation in esophageal carcinoma
Esophageal carcinoma (ESCA), comprising esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC), has a poor prognosis due to late diagnosis and incomplete molecular characterization. We sought to define the ESCA epigenomic landscape by integrating methylome and transcriptome data across both subtypes. TCGA-ESCA HumanMethylation450K and RNA-seq profiles (182 tumors: 95 ESCC and 87 EAC; 64 normal tissues) were analyzed using ELMER and Bioconductor workflows. Differentially methylated probes were annotated by genomic category, probe-gene coupling was tested by Spearman correlation, and a LASSO-penalized 12-CpG classifier was trained and externally validated in an independent GEO cohort (GSE68303; n = 43). ESCA showed pervasive enhancer hypomethylation, with 72.5% of the hypomethylated probes mapping to the distal enhancers. Methylation-expression coupling identified LINC02547 and PYGL as candidate effector genes, and enriched transcription factor motifs included AP-1 and NFIL3. The classifier achieved a cross-validated AUC of 0.996, approximately 0.99, sensitivity at 95% specificity, and reproducible performance across ESCC and EAC subtypes. Advanced disease stage was the dominant prognostic factor in multivariable survival models. Enhancer hypomethylation is a hallmark of ESCA, nominating LINC02547 and PYGL as biomarker candidates with diagnostic/prognostic promise. Limitations include retrospective design and need for experimental validation.
- 3 April 2026
- Published by Taylor & Francis in Epigenomics
- Vol. 18 (4) , 397-410
Computational-based integrative methylome-transcriptome analysis reveals widespread enhancer hypomethylation in esophageal carcinoma
Esophageal carcinoma (ESCA), comprising esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC), has a poor prognosis due to late diagnosis and incomplete molecular characterization. We sought to define the ESCA epigenomic landscape by integrating methylome and transcriptome data across both subtypes. TCGA-ESCA HumanMethylation450K and RNA-seq profiles (182 tumors: 95 ESCC and 87 EAC; 64 normal tissues) were analyzed using ELMER and Bioconductor workflows. Differentially methylated probes were annotated by genomic category, probe-gene coupling was tested by Spearman correlation, and a LASSO-penalized 12-CpG classifier was trained and externally validated in an independent GEO cohort (GSE68303; n = 43). ESCA showed pervasive enhancer hypomethylation, with 72.5% of the hypomethylated probes mapping to the distal enhancers. Methylation-expression coupling identified LINC02547 and PYGL as candidate effector genes, and enriched transcription factor motifs included AP-1 and NFIL3. The classifier achieved a cross-validated AUC of 0.996, approximately 0.99, sensitivity at 95% specificity, and reproducible performance across ESCC and EAC subtypes. Advanced disease stage was the dominant prognostic factor in multivariable survival models. Enhancer hypomethylation is a hallmark of ESCA, nominating LINC02547 and PYGL as biomarker candidates with diagnostic/prognostic promise. Limitations include retrospective design and need for experimental validation.
- Open Access
- 30 December 2025
- Published by MDPI AG in Applied Nano
- Vol. 7 (1) , 1
Comparative Characterization and Evaluation of WS6 Loaded Nanoformulations Using Solid Lipid, PLGA, and PCL Versus Eudragit RS/RL Prepared by Microfluidics
Objectives: This study aimed to optimize WS6-loaded nanoparticles (NPs) with favorable therapeutic properties, including appropriate size, low toxicity, high encapsulation efficiency, and enhanced biocompatibility, for selective cancer targeting and regenerative applications. Methods: Three formulations were investigated: solid lipid nanoparticles (SLNs), polycaprolactone (PCL)-based NPs, and Eudragit RS100-based NPs via microfluidic synthesis. Their physicochemical properties were assessed, followed by biological evaluation on normal cells—dental-derived stem cells (DSCs), gingival fibroblasts (GFs), and human dermal fibroblasts (HDFs)—and cancer cell lines MDA-231 and HepG2. Assays included MTT for viability, apoptosis/necrosis, cell cycle analysis, ROS detection, and cytokine profiling. Results: SLNs showed inherent toxicity despite improved viability upon WS6 loading. PCL NPs improved encapsulation and compatibility but lacked stability. The microfluidic RS-WS6 NPs exhibited optimal characteristics, significantly enhancing viability in normal cells and selectively inducing apoptosis in cancer cells. At 1 µM, RS-WS6 NPs reduced ROS in normal cells (p < 0.05) and increased it in cancer cells (p < 0.05). Cytokine analysis revealed significant downregulation of IL-6, IL-12p70, and TNF-α (p < 0.05), indicating immunomodulatory potential. Conclusions: RS-WS6 NPs developed via microfluidics offer a promising therapeutic platform with selective cytotoxicity against cancer cells, minimal toxicity to normal cells, and anti-inflammatory properties, supporting their use in targeted therapy and regenerative medicine.
- 30 December 2025
- Published by MDPI AG in Applied Nano
- Vol. 7 (1) , 1
Open AccessComparative Characterization and Evaluation of WS6 Loaded Nanoformulations Using Solid Lipid, PLGA, and PCL Versus Eudragit RS/RL Prepared by Microfluidics
Objectives: This study aimed to optimize WS6-loaded nanoparticles (NPs) with favorable therapeutic properties, including appropriate size, low toxicity, high encapsulation efficiency, and enhanced biocompatibility, for selective cancer targeting and regenerative applications. Methods: Three formulations were investigated: solid lipid nanoparticles (SLNs), polycaprolactone (PCL)-based NPs, and Eudragit RS100-based NPs via microfluidic synthesis. Their physicochemical properties were assessed, followed by biological evaluation on normal cells—dental-derived stem cells (DSCs), gingival fibroblasts (GFs), and human dermal fibroblasts (HDFs)—and cancer cell lines MDA-231 and HepG2. Assays included MTT for viability, apoptosis/necrosis, cell cycle analysis, ROS detection, and cytokine profiling. Results: SLNs showed inherent toxicity despite improved viability upon WS6 loading. PCL NPs improved encapsulation and compatibility but lacked stability. The microfluidic RS-WS6 NPs exhibited optimal characteristics, significantly enhancing viability in normal cells and selectively inducing apoptosis in cancer cells. At 1 µM, RS-WS6 NPs reduced ROS in normal cells (p < 0.05) and increased it in cancer cells (p < 0.05). Cytokine analysis revealed significant downregulation of IL-6, IL-12p70, and TNF-α (p < 0.05), indicating immunomodulatory potential. Conclusions: RS-WS6 NPs developed via microfluidics offer a promising therapeutic platform with selective cytotoxicity against cancer cells, minimal toxicity to normal cells, and anti-inflammatory properties, supporting their use in targeted therapy and regenerative medicine.